Psoriatic Arthritis Market, By Drug Class (DMARD, NSAIDs, Biologics, and Others), By Product Type (OTC and Prescriptions), By Route of Administration (Oral, Topical, and Injectable), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, and Forecast till 2029

Psoriatic arthritis is a type of arthritis that affects some people with psoriasis - a disease that causes red patches with silvery scales on the skin. Symptoms include joint pain, stiffness, and swelling, which may flare up and subside. Many people with this condition suffer from morning stiffness, Psoriatic arthritis is affect joints on one or both sides of your body. The signs and symptoms of psoriatic arthritis are often similar to rheumatoid arthritis. Both diseases cause joint pain, swelling and warmth to the touch. The increasing prevalence of psoriatic arthritis, an autoimmune disorder caused by the body's immune system attacking the joints and skin, is poised to increase the demand for psoriatic arthritis drugs for treatment. A stressful lifestyle leads to overstimulation of the immune system; Rapid growth of geriatric population, increasing prevalence of psoriasis, rising incomes leading to increased affordability for high-cost biological products, and increasing number of new product approvals are some of the major factors driving the growth of the psoriatic arthritis treatment market. The global psoriatic arthritis market accounted for US$ 6.9 billion in 2020 and is estimated to be US$ 14.8 billion by 2029 and is anticipated to register a CAGR of 9.0%.

Rise in Prevalence of Psoriatic Arthritis and Advancement in the therapeutics

Psoriatic arthritis patients are increasing every year. According to a publication in the International Journal of Clinical Rheumatology, psoriatic arthritis is considered a part of the spondyloarthritis group, which is present in 42% of individuals with psoriasis and 15% of patients with psoriasis may have undiagnosed psoriatic arthritis. Increase in drugs along with increasing cases and thereby diagnosis is driving the psoriatic arthritis market. Advances in the development of personalized medicine have been made over the past few years. It cannot target the exact location, tissue or region that needs to be treated.

Restraints:

                                                Adverse Effects of the Drugs

Advances in drug development have been very beneficial for treatment. However, these advanced complex drugs have some adverse effects on human health. For example, NSAIDs. Nonsteroidal anti-inflammatory drugs (NSAIDs) can relieve pain and reduce inflammation, but side effects can include stomach irritation, heart problems, and liver and kidney damage. Further, disease-modifying anti-rheumatic drugs (DMARDs) can slow the progression of psoriatic arthritis and prevent permanent damage to joints and other tissues. However, side effects can vary but can include liver damage, bone marrow suppression, and serious lung infections. This can act as a deterrent to the market.

Technological advancement

Key trends in the market include increasing involvement of government regulatory agencies to transform the healthcare and medical sector using new techniques, increasing drug adoption for psoriatic arthritis pain, drug launches, inorganic activities such as collaborations, and others. Recent technologies such as cytometry by time of flight (CyTOF), which detects heavy metals conjugated to cell-specific antibodies, and single-cell RNA sequencing (scRNAseq), based on the analysis of RNA expression in single cells—provide new insights into key effector cell subsets in the skin and Synovial fluid responsible for initiation and perpetuation of disease.

In September 2022, Pfizer Advances Vaccine Programs and Invests in Nimbus, Pfizer is leveraging funding and experience with vaccines for meningococcal, flu and RSV to further expand its presence in these areas. Pfizer's investigational pentavalent meningococcal vaccine was effective on all primary and secondary endpoints in a Phase III clinical trial in people aged 10 to 25 years.

Source: Prophecy Market Insights

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

The global psoriatic arthritis market is segmented based on the drug class, product type, route of administration and region.

Depending upon the drug class segment the global psoriatic arthritis market is divided into the DMARD, NSAIDs, biologics, and others. In terms of product type, the target market is segmented into OTC and prescriptions. Based on the route of administration, the target market is segmented into oral, topical, and injectable. The global active psoriatic arthritis market is segmented into prescription, OTC and others. The prescription segment dominated the other segments in terms of revenue share in the global market in 2020. Increasing prevalence of active psoriatic arthritis, increasing demand for advanced psoriatic arthritis treatments, and increasing sales of biologics and biosimilars as prescription drugs for psoriatic arthritis are some of them. Primary factors driving the revenue growth of this segment.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On region the Global Psoriatic Arthritis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe, collectively dominates the global psoriatic arthritis market mainly due to the commercial sales of products in the U.S. In addition, the presence of key manufacturers, proactive government initiatives, favorable reimbursement policies, and a large patient pool support the psoriatic arthritis treatment market growth. Further the market is expected to grow the fastest in the regions of Asia Pacific due to the overall economic development, improvement in healthcare infrastructure, increase in disposable income, and rise in consumer awareness.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the Global Psoriatic Arthritis Market report based on drug class, product type, route of administration and region:

Global Psoriatic Arthritis Market, By Drug Class:

• DMARD
• NSAIDs
• Biologics
• Others

Global Psoriatic Arthritis Market, By Product Type:

• OTC
• Prescriptions

Global Psoriatic Arthritis Market, By Route of Administration:

• Oral
• Topical
• Injectable

Global Psoriatic Arthritis Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating the Global Psoriatic Arthritis Market includes AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., AstraZeneca plc; Bausch Health Companies Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer, Inc. and UCB S.A. Strategic. For instance, In September 2022 Acelyrin sets hopes high for arthritis drug with $300M fundraise. Bosch Health's Silics target the related IL-17 receptor A. Studies show that drugs that stop IL-17 from binding to its receptor can reduce inflammation, as well as swelling and pain. Many are approved to treat psoriatic arthritis and other inflammatory conditions.

In July 2022, Bausch takes hit in Xifaxan patent feud, potentially paving the way for Norwich's IBS-D generic. Bausch Health has been dealt a blow in court after other copycats of its irritable bowel syndrome diarrhea (IBS-D) drug Xifaxan were routed. The court order opens up the possibility of Norwich Pharmaceuticals' proposed generic entering the market.

• AbbVie Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• AstraZeneca plc
• Bausch Health Companies Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Novartis International AG
• Eli Lilly and Company
• Pfizer, Inc.
• UCB S.A. Strategic.

 “*” marked represents similar segmentation in other categories in the respective section